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The  congenital  myopathies  – including  Central  Core  Disease  (CCD),  Multi-minicore  Disease  (MmD),  Cen-
tronuclear  Myopathy  (CNM),  Nemaline  Myopathy  (NM)  and  Congenital  Fibre  Type  Disproportion  (CFTD)
–  are  a  genetically  heterogeneous  group  of early-onset  neuromuscular  conditions  characterized  by dis-
tinct histopathological  features,  and  associated  with  a substantial  individual  and  societal  disease  burden.
Appropriate  supportive  management  has  substantially  improved  patient  morbidity  and  mortality  but
there  is currently  no  cure.
Recent  years  have  seen  an  exponential  increase  in the  genetic  and  molecular  understanding  of  these
conditions,  leading  to the  identification  of  underlying  defects  in proteins  involved  in  calcium  homeostasis
and  excitation-contraction  coupling,  thick/thin  filament  assembly  and function,  redox  regulation,  mem-
brane trafficking  and/or  autophagic  pathways.  Based  on these  findings,  specific  therapies  are  currently
being  developed,  or are  already  approaching  the  clinical  trial stage.  Despite  undeniable  progress,  therapy
development  faces  considerable  challenges,  considering  the  rarity  and  diversity  of specific  conditions,
and  the  size  and complexity  of  some  of  the  genes  and  proteins  involved.
The present  review  will summarize  the key  genetic,  histopathological  and  clinical  features  of  specific
congenital  myopathies,  and  outline  therapies  already  available  or  currently  being  developed  in  the  con-
text of known  pathogenic  mechanisms.  The  relevance  of  newly  discovered  molecular  mechanisms  and
novel  gene  editing  strategies  for  future  therapy  development  will  be  discussed.
© 2016  Elsevier  Ltd. All  rights  reserved.ontents
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. Introduction
The congenital myopathies are a group of clinically hetero-
eneous, early-onset neuromuscular disorders characterized by
ormal CK and defined features on muscle biopsy (for review, [1]).
entral Core Disease (CCD) and Multi-minicore Disease (MmD)
the “core myopathies”), Nemaline Myopathy (NM), Centronuclear
yopathy (CNM) and Congenital Fibre Type Disproportion (CFTD)
re the major entities. There are additional rarer forms, often lim-
ted to few families or patients.
The last decade has seen an exponential increase in the genetic
esolution of the congenital myopathies. Mutations in almost
0 genes have been identified (Table 1), indicating both genetic
iversity and substantial overlap between conditions previously
onsidered to be distinct. Different mutations in the same gene
ay  cause distinct congenital myopathies depending on the pro-
ein domain affected, whilst mutations in different genes may  cause
verlapping histopathological appearances due to functional asso-
iation of the defective gene products. Mutations in the skeletal
uscle ryanodine receptor (RYR1) gene, encoding the principal sar-
oplasmic reticulum (SR) calcium release channel with a crucial
ole in excitation-contraction coupling, have emerged as the most
ommon genetic cause implicated in most of the major forms [2,3].
roteins affected in the congenital myopathies are involved in cal-
ium homeostasis and excitation-contraction coupling, thick/thin
lament assembly and interactions, redox regulation, vesicular
rafficking and/or autophagic pathways (Fig. 1). In contrast to the
ongenital muscular dystrophies, sarcolemmal integrity is usually
reserved, reflected in typically normal CK levels.
There is currently no cure for any of the congenital myopathiesPlease cite this article in press as: H. Jungbluth, et al., Current and fut
Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.semcdb.2016.08.004
nd management is largely supportive, aimed at preserving
obility and addressing orthopaedic, cardiorespiratory and other
ig. 1. Schematic representation of pathogenic mechanisms implicated in the con-
enital myopathies (selection). A significant proportion of proteins involved in the
ongenital myopathies play a role in various aspects of Excitation-Contraction (EC)
oupling, the process by which a neuronal impulse is translated into muscle con-
raction, mediated by calcium release from the sarcoplasmic reticulum (SR) into the
ytosol and resulting in contractile thin/thick filament interactions. Abnormalities
f  the triad, the ultrastructural correlate of the EC machinery, are also an important
ownstream effect of defective membrane formation and remodelling in various
enetic forms of CNM due to mutations in MTM1,  DNM2 and BIN1. . . . .  . .  .  .  . . .  . .  .  . . . . . . .  . . . . .  . . .  . .  . . . . . .  . .  .  . . .  .  .  . .  . . .  .  .  .  . .  .  .  .  .  . . . .  . . . . .  .  . .  .  .  .  . .  00
potential comorbidities such as an increased malignant hyperther-
mia  (MH) risk (outlined in detail in [4]).
Therapy development in the congenital myopathies faces a
number of clinical and molecular challenges, some in common
with other early-onset neuromuscular disorders and others more
specific. On the clinical level, overall rarity of specific conditions
and the marked clinical diversity associated with specific genetic
defects makes recruitment for meaningful clinical trials a daunt-
ing task. On the molecular level, the sheer size and complexity of
some of the proteins involved precludes viral transfer of the func-
tional gene or exon skipping strategies as viable therapeutic options
in many of these conditions. In addition, some of the underlying
mechanisms are currently only partially understood.
The present review will summarize the key features of specific
congenital myopathies, relevant animal models, and underlying
pathogenic mechanisms (where known) as a basis for therapy
development. We  will outline currently available therapeutic
approaches (Table 1) and the rationale behind potential future
treatment strategies.
2. Core myopathies
The core myopathies (for detailed review, see [5]) are charac-
terized by variable histopathological abnormalities on oxidative
enzyme stains, well-defined and running along the longitudinal
fibre axis in Central Core Disease (CCD) [6], and of more limited
extent and patchier appearance in Multi-minicore Disease (MmD)
[7]. As a group, core myopathies represent the most common subset
of congenital myopathies, as recently confirmed in two indepen-
dent studies from the USA and the United Kingdom [2,3]. Core
myopathies are most commonly linked to dominant and recessive
mutations in the RYR1 gene, or recessive mutations in the SEPN1
gene encoding selenoprotein N. The histopathological appearance
of cores on muscle biopsy is, however, not specific, and other
genetic backgrounds, for example mutations in TTN [8] or MYH7
[9] have to be considered, in particular if cardiac involvement is a
feature and/or minicores are present.
Dominant mutations in RYR1 are most commonly associated
with the malignant hyperthermia susceptibility (MHS) trait [10],
a pharmacogenetic reaction to halogenated anaesthetics and mus-
cle relaxants, and CCD, a relatively mild, predominantly proximal
congenital myopathy typically without significant extraocular or
cardiorespiratory involvement. MHS-related RYR1 mutations have
also been associated with ‘induced’ or adult-onset neuromus-
cular phenotypes, in particular exertional rhabdomyolysis [11]
and late-onset axial myopathy [12]. Recessive mutations in RYR1
mainly cause Multi-minicore Disease with external ophthalmople-
gia [13], but also subgroups of Centronuclear Myopathy (CNM) [14]
and Congenital Fibre Type Disproportion (CFTD) [15] (see below).
Recessive mutations in SEPN1 are the second most common cause
of core myopathies [16], typically associated with the histopatho-
logical phenotype of MmD  and clinical features of a predominantly
axial myopathy with marked spinal rigidity, early-onset scoliosis
and respiratory impairment almost invariably requiring respira-
tory support; congenital muscular dystrophy with spinal rigidity
[17] and Mallory body myopathy [18] are allelic histopathologicalure therapeutic approaches to the congenital myopathies, Semin
presentations.
Whereas the pathomechanisms underlying dominantly inher-
ited RYR1-related MHS  and CCD have been investigated in detail,
recessive forms of RYR1-related myopathies remain only partially
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Table  1
Genetics of the major congenital myopathies. AD = autosomal dominant, AR = autosomal recessive, XLR = X-linked recessive inheritance. The most common genetic back-
grounds within each group are indicated in bold. *Typically combination of central nuclei and cores; **One isolated case with RYR1-related CNM and a de novo heterozygous
missense mutations has also been reported. *** typically combination of (central) nuclei, (mini)cores and other myofibrillar abnormalities.
Gene Locus Inheritance Protein
Nemaline myopathy
ACTA1 1q42 AD/AR skeletal - actin
CFL2  14q12 AR Cofilin-2
KBTBD13 15q25 AD Kelch 13
KLHL40 3p21 AR Kelch-like 40
KLHL41 2q31 AR Kelch-like 41
NEB  2q.2 AR Nebulin
TPM2 9p13 AD/AR -tropomyosin
TPM3 1q2 AD/AR -tropomyosin
TNNT1 19q13 AR Troponin T
Core  myopathies
Central Core Disease RYR1 19q13 AD/AR Ryanodine receptor 1
Multiminicore Disease RYR1 19q13 AD/AR Ryanodine receptor 1
SEPN1 1p36 AR Selenoprotein N1
+/−  cardiomyopathy TTN 2q31 AR Titin
MYH7 14q11 AD slow myosin heavy chain
Centronuclear myopathy
Myotubular myopathy MTM1  Xq28 XLR Myotubularin
Centronuclear myopathy BIN1 2q14 AR Amphiphysin
CCDC78 16p13.3 AD* coiled-coil domain- containing protein 78
DNM2 19p13 AD Dynamin-2
MYF6 12q21.31 AD Myogenic factor 6
RYR1 19q13 AR** Ryanodine receptor 1
SPEG 2q35 AR SPEG complex locus
TTN  2q31 AR*** Titin
Congenital Fibre Type Disproportion
ACTA1 1q42 AD skeletal -actin
HACD1 10p12 AR 3-hydroxyacyl-CoA dehydratase 1
MYH7 14q11 AD slow myosin heavy chain
RYR1 19q13 AR Ryanodine receptor 1
u
t
g
o
p
s
i
d
h
t
M
l
p
w
o
e
r
b
h
t
s
f
i
s
t
t
t
r
RSEPN1 1p36 
TPM2  9q13 
TPM3 1q2 
nderstood, with important implications for the development of
herapeutic strategies. Whilst MHS  and related phenotypes are
enerally attributed to a “hyperactive” RyR1 channel reflective
f increased RyR1 agonist sensitivity and resulting in dispro-
ortionate calcium release upon RyR1 stimulation, depletion of
arcoplasmic reticulum calcium stores with resulting increase
n cytosolic calcium levels (“leaky channel” hypothesis) and
isturbance of excitation-contraction coupling (E-C uncoupling
ypothesis) have been proposed as explanations for RyR1 recep-
or malfunction in CCD and related myopathies (reviewed in [5]).
ost functional studies concerning recessive RYR1 mutations pub-
ished to date indicate the marked reduction of the functional RyR1
rotein levels as an important common denominator in this group,
ith impairment of calcium conductance rather than alterations
f cytosolic or SR calcium levels as the most common downstream
ffect [19–21]. The precise function of selenoprotein N in muscle
emains still uncertain but emerging evidence suggests a role in
oth antioxidant defense systems and (redox-regulated) calcium
omeostasis: Selenoprotein N features a structural motif similar
o those found in calcium-binding proteins [17] and, as demon-
trated in normal zebrafish and the sepn1 −/− morphant, may  be
unctionally and spatially associated with RyR1 [22,23], provid-
ng a possible molecular basis for the many clinico-pathological
imilarities between RYR1- and SEPN1-related core myopathies.
Because of the rapid recognition of RYR1 mutations as one of
he most common causes of neuromuscular disorders in humans,Please cite this article in press as: H. Jungbluth, et al., Current and fut
Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.semcdb.2016.08.004
herapy development for these conditions is a major goal within
he congenital myopathy field. Possible therapeutic strategies cur-
ently considered or already tried include modification of abnormal
yR1 function, correction of associated oxidative abnormalities,AR Selenoprotein N1
AD -tropomyosin
AD -tropomyosin
use of pharmacological compounds enhancing muscle contractility
and/or neuromuscular transmission, and correction of the specific
genetic defect (Table 2).
Historically, the first pharmacological compound used to mod-
ify the abnormal Ca++ amount released during an MH crisis was
dantrolene, an agent that was shown in early studies to reduce
the maximal rate of SR Ca++ release [24] and inhibit caffeine
induced ryanodine binding. In addition to its well-established role
in MH management, dantrolene has also been used in the treat-
ment of patients with RYR1-related (exertional) rhabdomyolysis
[25], and anecdotal reports suggest that some patients with RYR1-
related CCD may  also benefit from dantrolene use [26,27]. However,
explorative use of dantrolene in RYR1-related myopathies ought
probably to be limited to those carrying “leaky channel” mutations
compared to those where calcium conductance is already reduced,
considering that a RyR1 antagonist such as dantrolene may  poten-
tially worsen the consequences of the molecular defect in the latter
group.
RyR1 channels are situated within a highly complex macro-
molecular environment and undergo a number of dynamic
modifications. One class of proteins involved in these complex
interactions that have emerged as a possible pharmacological
target for the treatment of RYR-related cardiac and skeletal
myopathies are the calstabins, including calstabin 1 (FK506 bind-
ing protein 12 or FKBP12) mainly expressed in skeletal muscle
and calstabin 2 (FKBP12.6) mainly expressed in cardiac muscle (forure therapeutic approaches to the congenital myopathies, Semin
review, [28,29]). Calstabins act as RyR1 channel-stabilising proteins
that increase the channel probability of being closed at the resting
state, but their dissociation from the RyR receptor under conditions
of stress and with increased phosphorylation and nitrosylation
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Table  2
Therapeutic approaches to the congenital myopathies. * = first clinical trials with N-acetylcysteine currently in progress.
Therapeutic approach CM Gene Type of study Reference
Gene therapy
Exon skipping CCD RYR1 Proof of Principle 41
Gene  transfer XLMTM MTM1 Proof of Principle 61
Enzyme replacement
Enzyme replacement therapy XLMTM MTM1 Proof of Principle 63
Modulation of SR calcium release
Dantrolene MH,  ERM RYR1 Case studies 26
Dantrolene CCD RYR1 Case studies 27
AICAR MH,  ERM RYR1 Proof of Principle 32
Rycals MH,  CCD RYR1 Proof of Principle 29
Modulation of neuromuscular transmission
Pyridostigmine CNM MTM1 Open-label pilot study 68
Pyridostigmine NM KLHL40 Case study 112
Salbutamol MmD,  CCD RYR1 Open-label pilot study 38
Modulation of filament interaction
CK-2017357 NM Various Proof of Principle 115
CK-1827452 NM Various Proof of Principle 116
Other approaches
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uMyostatin inhibition CNM 
N-Acetylcysteine CCD 
N-Acetylcysteine MmD  
esults in “leaky” channels and, ultimately, in reduction of the
vailable SR calcium stores. Two pharmacological compounds that
ave been demonstrated to reduce SR calcium leak by enhancing
yR1-calstabin interactions are the 1,4-benzothiazepine deriva-
ives JTV519 and S107 (also known as Rycals), suggesting them
s potential treatments also for RYR1-related myopathies associ-
ted with excessive calcium release such as MH or ERM, or with
ncreased SR calcium leak such as subgroups of CCD [30]. Concerns
emain regarding non-skeletal muscle effects of these compounds
riginally developed for the treatment of cardiac disease, and their
ffects in recessive RYR1-related myopathies where calcium con-
uctance may  already be impaired (and increasing RyR1 channel
losed probability may  potentially have a detrimental rather than
 beneficial effect).
Another compound that has been suggested to stabilize RyR1
unction is 5-aminoimidazole-4-carboximide ribonucleoside (or
ICAR),  an activator of the AMP-activated protein kinase (AMPK), a
inase and intracellular energy sensor upstream of the autophagy
athway. AICAR, a recognized enhancer of muscle performance
31], has recently been demonstrated to directly reduce RyR1 cal-
ium leak and RNS and ROS production, an important aspect of the
icious cycle leading to fatal rhabdomyolysis in a mouse model of
he human MH-  and ERM-associated RYR1 mutation Y522S [32].
hese findings suggest AICAR as a potential treatment for RYR1-
elated myopathies associated with excessive calcium release or
ncreased spontaneous calcium leak, but there are currently no data
egarding its longterm use in human myopathies.
Another altogether different treatment approach is based on
he observation of increased oxidative stress in patient cells and
nimal models. Recent studies have indicated that oxidative stress
ay  be one of the causes underlying MH,  and that oxidative stress
s elevated in muscle of patients with MH and RYR1- and SEPN1-
elated myopathies [33–35]. A study on patient muscle cells and
he zebrafish “relatively relaxed” mutant, a model of human reces-
ive RYR1-related myopathies lacking the skeletal muscle ryr1b
soform, demonstrated elevation of oxidative stress markers and
xcessive production of reactive oxygen species of probable mito-Please cite this article in press as: H. Jungbluth, et al., Current and fut
Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.semcdb.2016.08.004
hondrial origin. Treatment with 200 M N-acetylcysteine (NAC)
educed oxidative stress markers, decreased muscle damage and
mproved swimming abilities in the zebrafish mutant [35]. The
se of antioxidants (and more specifically, NAC) is also supportedM1 Proof of Principle 118
R1 Proof of Principle* 35
N1 Proof of Principle* 35
by the fact that the RyR1 protein contains more than 100 cys-
teine residues, and that some of these (namely Cys residues at
amino acid positions 1040, 1303, 2436, 2656, 2606, 2611 and 3635)
are hyper-reactive and act as redox sensors which modulate the
channel activity [36,37]. Taken together, these observations have
provided the rationale for the use of NAC as a potential treatment
for RYR1- and SEPN1-related myopathies, and have prompted the
first clinical trials in humans currently underway. However, there
are presently no data regarding its longterm use in these conditions,
and genetic determinants of altered oxidative stress susceptibility
(such Glucose 6-phosphate dehydrogenase (G6PD) deficiency, one
of the most common metabolic conditions worldwide) will have to
be taken into account for the interpretation of clinical trials.
Prompted by its previous use in other neuromuscular disorders,
the -agonist salbutamol has also been explored for the treatment
of core myopathies with encouraging results in case reports and
a small pilot study [26,38,39]. The precise mechanisms underly-
ing the benefits of salbutamol in core myopathies are uncertain,
but may  include an anabolic effect as seen in other -mimetics,
increases in relaxation speed and contractility as described in
cardiac muscle [40], and/or enhancement of neuromuscular trans-
mission.
The feasibility of genetic strategies to treat RYR1-related
myopathies has been demonstrated in one recessive case where
exon skipping was successfully applied in vitro to remove an
additional, paternally inherited exon associated with an unstable
transcript and reduced RyR1 protein expression [41], resulting in
increased expression of a functional RyR1 protein, and improved
myotube morphology. Although these results are highly encourag-
ing, a similar approach may  only be applicable to the small number
of pseudo-exon creating mutations in RYR1-related myopathies
(estimated at 1–2%), as, in contrast to large structural proteins such
as dystrophin, the RyR1 protein is unlikely to tolerate removal of
whole exons through exon skipping considering its highly com-
plex structure with probably little redundancy within functional
domains. However, considering that even marked reduction of
the functional RyR1 protein in carriers of recessive RYR1 muta-ure therapeutic approaches to the congenital myopathies, Semin
tions appears to be well tolerated [41,42], targeted gene editing
may  become a feasible strategy to silence selected dominant RYR1
mutations associated with CCD in the future. A general caveat
regarding the feasibility of gene therapy approaches to RYR1-
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elated myopathies concerns the relative scarcity of recurrent RYR1
utations, suggesting that many of these currently highly time
onsuming and costly targeted approaches may  only benefit a small
umber of (or even only isolated) families only.
Potential for future therapy development in RYR1-related
yopathies is suggested by the recent observation of altered
xpression levels of microRNAs (miRs) and histone deacetylyase
HDACs) in patients with recessive RYR1-related myopathies (for
urther details, see article by Treves et al. in this issue) [43,44].
icroRNAs are endogenous small (around ∼22 nucleotides), non-
oding RNAs that control gene expression by repressing translation
r enhancing RNA degradation and that have been implicated
n several cardiac and skeletal muscle pathologies. HDACs are
nvolved in gene transcription and sequester the muscle specific
ranscription factor mef2 [45]. The overexpression of class II HDACs,
n particular HDAC4 and 5, suggests those as potential pharmaco-
ogical targets, however, the precise role of such overexpression
as to be ascertained in the first instance before considering mod-
lating them as a feasible therapeutic strategy.
. Myotubular/Centronuclear Myopathy (MTM/CNM)
Myotubular (or Centronuclear) Myopathies (MTM/CNM) are
haracterized by abundance of central nuclei on muscle biopsy
for review, [46]). CNM is due to X-linked recessive mutations in
TM1  encoding myotubularin [“X-linked myotubular myopathy
XLMTM)”] [47], autosomal-dominant mutations in DNM2 encod-
ng dynamin2 [48] and the BIN1 gene encoding amphiphysin 2 [49],
utosomal-recessive mutations in BIN1 [50], RYR1 [14], and TTN
ncoding titin [51], and rarer backgrounds [52–54]. Whilst muta-
ions in MTM1  and BIN1 are typically associated with a “pure” CNM
icture, histopathological appearance in particular in DNM2-,  RYR1-
nd TTN-related forms is more variable and may  also feature cores,
FTD and dystrophic features [14,55,56]. XLMTM due to X-linked
ecessive MTM1  mutations is one of the most devastating neuro-
uscular disorders in humans with profound weakness, marked
espiratory impairment and substantial mortality in affected males,
hereas mutations in DNM2,  BIN1, TTN and RYR1 are associated
ith more variable but on the whole milder phenotypes (for review,
46]). Extraocular involvement is prominent in all forms except
TN-related CNM. Non-skeletal muscle involvement – for example
epatic peliosis in XLMTM [57], cataracts in DNM2-related CNM
58] and dilated cardiomyopathy in association with SPEG muta-
ions [54] – has been reported with different genetic backgrounds.
A wide range of cellular and organismic models of the vari-
us genetic forms of CNM have been developed in recent years,
s a basis for investigating underlying pathogenic mechanisms and
s a prerequisite for therapy development (reviewed in [59]). The
roteins initially implicated in CNM – myotubularin, dynamin 2
nd amphiphysin 2–are involved in intricately linked aspects of
embrane trafficking and (re)modelling (reviewed in [60]). More
pecific pathogenic mechanisms (downstream of above “mas-
er mechanisms”) (reviewed in [59]) include defects of triads
nd calcium handling, autophagy, the neuromuscular junction,
atellite cells, mitochondria, and the desmin cytoskeleton. RYR1-
elated CNM shares disturbed calcium homeostasis and defective
xcitation-contraction coupling as a common mechanism with
ther forms, but how mutations in TTN cause CNM is currently
ncertain.
Therapy development efforts in the CNMs have been mainly
ocussed on XLMTM, considering the profound severity of thePlease cite this article in press as: H. Jungbluth, et al., Current and fut
Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.semcdb.2016.08.004
isorder. The enzymatic functions of the myotubularin protein sug-
est enzyme replacement therapy as a therapeutic option, and
he relatively small size of the MTM1  gene allows for therapies
ased on viral gene transfer-based gene therapy. Delivery of func- PRESS
opmental Biology xxx (2016) xxx–xxx 5
tional myotubularin applying an AAV8-based vector has now been
demonstrated to improve the clinical and histopathological phe-
notype in Mtm1-deficient mice, and to increase muscle strength,
reduce respiratory impairment and prolong survival in a canine
model of XLMTM [61], the Labrador retriever [62]. Similar improve-
ments of contractile function and histopathological features have
been observed following short term myotubularin enzyme replace-
ment in Mtm1d4 mice [63]. Results from these animal studies have
been promising and have provided the basis for human enzyme
replacement and gene therapy trials currently in preparation.
Another potentially promising avenue for future therapy devel-
opment is prompted by recent experimental evidence indicating
that dynamin 2 downregulation may  rescue the XLMTM phenotype
in mice [64], emphasizing the close interaction of several CNM
proteins in the same pathway and suggesting dynamin 2 down-
regulation as a possible therapeutic strategy for XLMTM.
As with for other conditions caused by heterozygous gain-of-
function or dominant-negative mutations, dominant forms of CNM
due to DNM2 or BIN1 mutations may  also be amenable to recently
introduced gene editing strategies once those will approach the
stage of clinical application [65].
Another therapeutic approach is based on the observation of
neuromuscular junction (NMJ) abnormalities in patients and ani-
mal  models of CNM [66], and the clinical overlap between the CNMs
and certain forms of congenital myasthenic syndromes (CMS), sug-
gesting pharmacological compounds enhancing neuromuscular
transmission as a potential treatment modality [67,68]. One such
compound, pyridostigmine, has already been demonstrated to be
of benefit in patients with genetically confirmed and unresolved
forms of CNM [67,68]. Salbutamol is another drug that has been
used effectively in certain subgroups of CMS  and may  also be of
benefit in other congenital myopathies as outlined above [38].
However, those observations were only based on small pilot studies
and no large placebo-controlled double-blind studies concerning
these compounds have been performed yet.
4. TTN-related myopathies
Although recessive TTN mutations have been linked with
CNM [51], there is considerable overlap with other congenital
myopathies, in particular the core myopathies [8,56], and TTN-
related myopathies are therefore covered here in a separate
paragraph. The treatment approaches discussed below may also be
potentially relevant to genes of similar size and mutation profiles
such as NEB, and/or other proteins where abnormal aggregation
may  be an issue.
Due to the large size of the TTN gene, its many exons, and a
protein molecular weight of over 3 million Dalton, titin is highly
susceptible to the stochastic impact of mutagenesis [69]. Premature
stop-codons (caused by either mutations affecting correct splicing
and leading to the inclusion of intronic sequences, or exonic non-
sense mutations) as well as numerous missense variants abound
in the TTN gene, with their functional impact and pathogenic rel-
evance often difficult to ascertain. In CNM and other TTN-related
Paediatric congenital myopathies reported to date, these variants
are recessive [8,51,56,70]. Although most TTN variants are pri-
vate or very rare, some recessive missense variants have been
linked to Autosomal-Recessive Multi-minicore Disease with Heart
Disease (AR MmD-HD), with clear functional indication of struc-
tural disruption and complete loss of function of some key titin
domains [8]. It appears that almost any combination of truncatingure therapeutic approaches to the congenital myopathies, Semin
and disruptive missense mutations in TTN can cause early-onset
congenital myopathies with often vastly variable phenotypes, pos-
ing formidable challenges for accurate diagnostics but also for the
development of therapeutic strategies that are realistically employ-
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ble within the constraints of real clinical settings. Considering the
ain mutation mechanisms, several treatment strategies can be
onceived and are pursued already in different contexts:
I In the presence of nonsense mutations, restoring the mRNA
reading frame (either by exon-skipping or suppression of pre-
mature stop codons) could restore a functionally useful protein
with largely intact mechanical and signalling functions and the
potential to rescue or ameliorate the disease phenotype. This
approach has been developed for the treatment of Duchenne
muscular dystrophy (DMD), by exploiting initially the ability
of certain aminoglycosides to enhance premature stop-codon
read-through [71] and subsequent development of compounds
with a similar mechanism of action but reduced toxicity such as
PTC124 (Ataluren). Pharmacological suppression of premature
stop codons is potentially applicable to a wide range of diseases,
and pre-clinical and clinical studies are ongoing at various stages
for DMD, cystic fibrosis, Werner Syndrome and other conditions
[72–75], and should clarify the long-term clinical outcomes in
comparison to established therapies. This approach should also
be applicable to TTN truncating nonsense mutations, informed
by prior studies in cellular and/or animal titinopathy models
as a screening platform for the feasibility of stop-codon read-
through therapy. It is not yet clear if the efficacy of ataluren is
high enough to restore functional levels of dystrophin or titin
to regain significant structural integrity and function, which is
clearly easier with enzymes or ion channels where (partial) func-
tional rescue can be achieved with much lower stoichiometry.
An interesting point is whether the simultaneous intervention
in other loss-of-function loci will be beneficial. MacArthur et al.
estimated that the human genome contains around 100 loss-of-
function variants, with about 20 genes completely inactivated
[76]. The impact of these variants can be hard to predict, lead-
ing to loss of mRNA or protein by specific degradative pathways
[77]. This might pose not only a diagnostic problem (which trun-
cating gene variants are truly pathogenic?), but could also be a
challenge for global pharmacological read-through therapy that
would lead to the re-expression of such loss-of-function loci.
II The use of protein-stabilising chaperone-like compounds
(“chemical chaperones”) could be used to prevent the aggrega-
tion or degradation of misfolded titin domains carrying missense
variants, or to promote their clearance by protein degradation
pathways. This approach could alleviate the effects of pro-
teotoxicity if a more normal function of the abnormal protein
could be maintained. The recent use of the chemical chaper-
one 4-phenylbutyrate (4-PBA) demonstrated that this simple
compound is capable of ameliorating protein aggregate forma-
tion and restoring basic mechanical functions in cellular models
of plectinopathy [78], although it remains to be seen if these
promising results can be reproduced at the organismic level. The
chemical nature of 4-PBA leads to effects on multiple pathways,
with a well-documented ability to inhibit histone deacetylases
(HDAC) [79]. HDAC inhibition activates autophagy (for exam-
ple [80]), one of the two major ubiquitin-dependent protein
degradation pathways, and it is possible that the stimulation
of autolysosomal degradation of protein aggregates and thus
their reduced proteotoxicity, rather than primary prevention of
misfolding, might be mechanistically important in skeletal mus-
cle. Clearly, developing better and more specific small-molecule
inhibitors of protein aggregation could therefore add signifi-
cantly to the arsenal of hereditary myopathy therapy but might
require tailored approaches for certain classes or types of muta-Please cite this article in press as: H. Jungbluth, et al., Current and fut
Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.semcdb.2016.08.004
tions [81].
III In the case of haploinsufficiency, the absent protein would need
to be restored if the above strategies are not effective. Current
methods for gene delivery using chemical approaches or viral PRESS
opmental Biology xxx (2016) xxx–xxx
vectors are unsuited for gene or even protein delivery of a target
with an mRNA of over 80 kb, making this last approach unlikely
to be successful even in the medium future.
IV Compounds that directly target the biological activity of the
mutant protein to disrupt that pathomechanism at its causative
root. Such drug discovery is in its infancy for hereditary
myopathies, but recent advances for small molecules targeting
mutant beta-myosin and alleviating heart disease progression
in mouse models [82] suggest that such approaches might be
feasible in some cases. However, better understanding of the
underlying biology would be required to devise robust screening
protocols.
5. Nemaline myopathy (NM)
Nemaline myopathy (NM) is one of the more common con-
genital myopathies [2,83,84] characterized by numerous nemaline
rods on muscle biopsy. To date, 10 genes have been linked to this
disorder, including ACTA1,  NEB, TPM3, TPM2, CFL2, TNNT1,  LMOD3,
KBTBD13, KLHL40, and KLHL41 [84–86] of which recessive muta-
tions in NEB and (de novo) dominant mutations in ACTA1 are the
most common. NM is associated with highly variable degrees of
muscle weakness [2,83,84,87] ranging from profoundly affected
infants within the fetal akinesia spectrum to only mildly affected
adult-onset cases. Bulbar and respiratory impairment are common
in many genetic forms but extraocular muscle involvement is not a
typical feature, except in those due to mutations in the KLHL genes.
Seven of the 10 genes implicated in NM – i.e.,  skeletal alpha-actin
(ACTA1), nebulin (NEB), tropomyosin (TPM3 and TPM2), troponin T
(TNNT1), cofilin (CFL2) and leiomodin-3 (LMOD3) – encode proteins
constituting the sarcomeric thin filament [88,89]. The sarcomeric
thin filament is an essential component of normal muscle function,
through conformational changes allowing myosin head binding
to actin monomers and, ultimately, force production, prompted
by Ca2+ binding to one of its components, troponin C. To under-
stand how NM-related mutations disrupt normal thin filament
function, experimental studies have used muscle samples from NM
patients or from mouse models reproducing the human condition
[86,90–96]. These studies have revealed that the absence of certain
proteins (e.g. nebulin or skeletal alpha-actin), or the presence of
mutated amino acids in skeletal alpha-actin and tropomyosin, alter
Ca2+ binding, thin filament conformation and/or the interaction
between myosin and actin molecules [86,95,97–108], resulting in
reduced force generation at the sarcomere and, ultimately, skeletal
muscle weakness.
Despite improved understanding of the pathophysiological
mechanisms underlying skeletal muscle weakness in NM,  there
is currently no cure and management is mainly symptomatic
[109,110], but a number of pharmacological compounds and
supplements have been tested. Supported by preclinical data in
a mouse model of ACTA1-related NM [90], a pilot study in 5
patients with NM suggested a beneficial effect of l-tyrosine, with
reduced fatigue and improvement of drooling [111]. A recent
report of a single case with severe KLHL40-related NM sug-
gested a sustained beneficial response to the acetylcholinesterase
inhibitor pyridostigmine [112], indicating an associated neuro-
muscular transmission defect potentially amenable to treatment,
corresponding to observations in other congenital myopathies, in
particular the CNMs (see above).
Considering the key role of thin filament dysfunction in NM,
drugs targeting thin filaments and their interactions directly haveure therapeutic approaches to the congenital myopathies, Semin
been recently developed [113,114]. CK-2017357 (Cytokinetics Inc.)
binds to the Ca2+ sensor, troponin C, thereby facilitating force pro-
duction by slowing the rate of Ca2+ release from troponin C and
consequently favouring myosin activation and impairing the relax-
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tion process [115]. However, a possible clinical benefit in NM is
ncertain as CK-2017357 preferentially affects fast-twitch mus-
le fibres which are typically lacking in NM.  Another compound,
mecamtiv Mecarbil (formerly termed CK-1827452) (Cytokinet-
cs Inc.) attaches to myosin molecules and could be potentially
dvantageous for weak slow-twitch muscle fibres [116]. However,
mecamtiv Mecarbil also binds to cardiac myosin molecules, rais-
ng the possibility of cardiac complications if given to patients with
M.
Considering the difficulties with directly targeting thin filament
unction, other therapeutic strategies are currently being devel-
ped. Muscle tissue from patients or animal models of NM contains
 large number of atrophic fibres [2,83,84], suggesting increas-
ng muscle fibre size and overall muscle mass by using myostatin
nhibitors as a possible therapeutic strategy. Myostatin is a protein
hat is selectively expressed in skeletal muscle, cardiac muscle, and
dipose tissue during late embryogenesis and adulthood and is an
mportant negative regulator of muscle fibre size [117]. It binds to
nd signals through the activin type IIB receptor (ActRIIB) to down-
egulate several key processes related to muscle fibre hypertrophy
117]. The potential for myostatin inhibition to promote muscle
rowth has led to development of a new class of myostatin and
ctRIIB inhibitors as prospective therapeutic agents for myopathic,
ystrophic and neurologic disorders [117], including NM but poten-
ially also other congenital myopathies where fibre atrophy is a
rominent feature such as XLMTM [118].
In the context of ACTA1-related NM,  muscles from patients with
are null mutations partially compensate the absence of skeletal
uscle -actin by expressing the ACTC-associated protein, car-
iac -actin [119]. These findings have prompted investigation of
ardiac -actin upregulation as a possible therapeutic avenue in
arious mouse models of ACTA1-related NM.  In one transgenic line
arrying the D286G mutation, muscle weakness and lethality were
ignificantly reduced whilst in another model expressing H40Y, the
p-regulation of ACTC did not have any noticeable positive or ben-
ficial effect [120]. The mechanisms underlying such discrepancies
emain to be determined.
. Congenital Fibre Type Disproportion
Congenital Fibre Type Disproportion (CFTD) is most commonly
efined by type 1 fibres being at least 25% smaller than type 2 fibres
n the absence of other pathological features on muscle biopsy (for
eview [121]). There is marked genetic and clinico-pathological
verlap with other congenital myopathies, in particular NM and
YR1-related myopathies, and although in many patients the
istopathological appearance of “pure” CFTD persists, in others
dditional histopathological features such as nemaline rods, central
uclei or cores may  evolve over time [15,122–127]. CFTD is most
ommonly due to mutations in TPM3 and RYR1 and less frequently
ue to mutations in ACTA1 and SEPN1.  Although there are currently
o therapeutic approaches specifically aimed at CFTD, these dis-
rders are likely to benefit from therapy developments in other
losely related congenital myopathies.
. Conclusions and outlook
Although there is currently no cure for any of the congeni-
al myopathies, therapy development is rapidly progressing and
nformed by recent exponential advances concerning the genetic
nd molecular understanding of these conditions. Based on ani-Please cite this article in press as: H. Jungbluth, et al., Current and fut
Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.semcdb.2016.08.004
al experimental evidence, gene therapy and enzyme replacement
herapy trials are in preparation for X-linked myotubular myopathy
XLMTM), one of the most severe congenital myopathies. Clinical
rials in humans with acetylcysteine in humans with SEPN1-  and PRESS
opmental Biology xxx (2016) xxx–xxx 7
RYR1-related myopathies are currently in progress, based on the
observation of marked oxidative abnormalities as an important
pathogenic mechanism in these conditions. Off-label use of drugs
such as dantrolene, pyridostigmine and salbutamol appears to be
of benefit in small open-label pilot studies, but those findings will
have to be confirmed in larger double-blind, placebo-controlled
clinical trials. Unravelling novel disease mechanisms may lead
to the development of therapies potentially applicable to several
genetically distinct subgroups in subgroups intricately linked in the
same molecular pathways. Novel gene editing strategies may  pro-
vide new therapeutic options in particular for dominantly inherited
conditions in future but do raise significant ethical questions asso-
ciated with direct manipulation of the human genome.
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